Liver Cirrhosis - Pipeline Review, H2 2016

Date: August 31, 2016
Pages: 86
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: L32A25C0F0BEN
Leaflet:

Download PDF Leaflet

Liver Cirrhosis - Pipeline Review, H2 2016

SUMMARY

Global Markets Direct’s, ‘Liver Cirrhosis - Pipeline Review, H2 2016’, provides an overview of the Liver Cirrhosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Liver Cirrhosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Liver Cirrhosis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Liver Cirrhosis
  • The report reviews pipeline therapeutics for Liver Cirrhosis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Liver Cirrhosis therapeutics and enlists all their major and minor projects
  • The report assesses Liver Cirrhosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Liver Cirrhosis
REASONS TO BUY
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Liver Cirrhosis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Liver Cirrhosis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Liver Cirrhosis Overview
Therapeutics Development
Pipeline Products for Liver Cirrhosis - Overview
Pipeline Products for Liver Cirrhosis - Comparative Analysis
Liver Cirrhosis - Therapeutics under Development by Companies
Liver Cirrhosis - Therapeutics under Investigation by Universities/Institutes
Liver Cirrhosis - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Liver Cirrhosis - Products under Development by Companies
Liver Cirrhosis - Products under Investigation by Universities/Institutes
Liver Cirrhosis - Companies Involved in Therapeutics Development
Conatus Pharmaceuticals Inc.
Digna Biotech, S.L.
Galectin Therapeutics, Inc.
Human Stem Cells Institute
Nimbus Therapeutics, LLC
Ocera Therapeutics, Inc.
Pharmicell Co., Ltd.
S-Evans Biosciences, Inc.
Stelic Institute & Co., Inc.
Liver Cirrhosis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Cellgram-LC - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DB-027 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DB-036 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
emricasan - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gemacell - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GRMD-02 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GXHPC-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ND-654 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ornithine phenylacetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit NLRP3 for Liver Cirrhosis and Non-Alcoholic Steatohepatitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Articular Cartilage Defect, Cerebral Hemorrhage, Liver Cirrhosis and Pneumoconiosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Liver Cirrhosis and Rheumatoid Arthritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Liver Fibrosis and Liver Cirrhosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Metabolic, Gastrointestinal, Multiple Organ Failure and Respiratory Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
STNM-04 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Liver Cirrhosis - Dormant Projects
Liver Cirrhosis - Discontinued Products
Liver Cirrhosis - Product Development Milestones
Featured News & Press Releases
May 04, 2016: Conatus Extends Positive Results with Emricasan in Phase 2 Liver Cirrhosis Clinical Trial
Apr 18, 2016: Conatus Late Breaker Oral Presentation at EASL Details Phase 2 Liver Cirrhosis Trial Three-month Data
Mar 30, 2016: Conatus Pharmaceuticals Announces Late Breaker Oral Presentation on Emricasan at EASL Meeting
Jan 05, 2016: Conatus Achieves Positive Results with Emricasan in Initial Stage of Phase 2 Liver Cirrhosis Clinical Trial
Nov 16, 2015: Conatus Pharmaceuticals Announces Late-Breaking Oral Presentation at AASLD Annual Meeting
Nov 16, 2015: Conatus Pharmaceuticals Announces Poster Presentations at AASLD Annual Meeting
Oct 20, 2015: Conatus Pharmaceuticals Announces Acceptance of Late-Breaking Abstract for AASLD Annual Meeting
Oct 01, 2015: Conatus Pharmaceuticals Announces Acceptance of Abstracts for AASLD Annual Meeting
Jun 25, 2015: Conatus Announces Initial Baseline Data From Phase 2b POLT-HCV-SVR Clinical Trial of Emricasan Confirming Activity of Relevant Mechanisms and Opportunity for Histological Improvement
May 14, 2015: Galectin Therapeutics Reports no Drug-Drug Interaction Between GR-MD-02 and Midazolam
Nov 10, 2014: Conatus Pharmaceuticals Presents Late-Breaking Poster At AASLD Annual Meeting
Oct 08, 2014: Conatus Pharmaceuticals Announces Acceptance Of Late-Breaking Abstract For AASLD Annual Meeting
Sep 02, 2014: Conatus Pharmaceuticals Initiates Phase 2 Trial in Patients with Liver Cirrhosis and Separate Open Label Phase 2 Trial in Cirrhosis Patients with Portal Hypertension
Jul 23, 2012: Galectin Therapeutics Receives US Patent for Potential Treatment for Chronic Liver Disease with Fibrosis And Cirrhosis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Liver Cirrhosis, H2 2016
Number of Products under Development for Liver Cirrhosis - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Liver Cirrhosis - Pipeline by Conatus Pharmaceuticals Inc., H2 2016
Liver Cirrhosis - Pipeline by Digna Biotech, S.L., H2 2016
Liver Cirrhosis - Pipeline by Galectin Therapeutics, Inc., H2 2016
Liver Cirrhosis - Pipeline by Human Stem Cells Institute, H2 2016
Liver Cirrhosis - Pipeline by Nimbus Therapeutics, LLC, H2 2016
Liver Cirrhosis - Pipeline by Ocera Therapeutics, Inc., H2 2016
Liver Cirrhosis - Pipeline by Pharmicell Co., Ltd., H2 2016
Liver Cirrhosis - Pipeline by S-Evans Biosciences, Inc., H2 2016
Liver Cirrhosis - Pipeline by Stelic Institute & Co., Inc., H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Liver Cirrhosis - Dormant Projects, H2 2016
Liver Cirrhosis - Discontinued Products, H2 2016

LIST OF FIGURES

Number of Products under Development for Liver Cirrhosis, H2 2016
Number of Products under Development for Liver Cirrhosis - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

COMPANIES MENTIONED

Conatus Pharmaceuticals Inc.
Digna Biotech, S.L.
Galectin Therapeutics, Inc.
Human Stem Cells Institute
Nimbus Therapeutics, LLC
Ocera Therapeutics, Inc.
Pharmicell Co., Ltd.
S-Evans Biosciences, Inc.
Stelic Institute & Co., Inc.
Skip to top


Cirrhosis - Pipeline Review, H2 2014 US$ 1,500.00 Jul, 2014 · 67 pages

Ask Your Question

Liver Cirrhosis - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: